Antiprogestin therapies are being actively studied for breast (and other) cancers (reviewed in [19, 83]); therefore, a more comprehensive understanding of the differences in transcriptional regulation by these ligands (in relation to PR posttranslational modifications) will be critical. Here, PGR is linked to cancer.